Experiment Protocol Biomedical Engineer in Italy Milan –Free Word Template Download with AI

Principal Investigator: Dr. Alessandro Rossi, Biomedical Engineer
Co-Investigator: Dr. Giulia Bianchi, Clinical Physiologist

This Experiment Protocol outlines the rigorous methodology required for the validation of a novel non-invasive hemodynamic monitoring system. As a Biomedical Engineer operating within the prestigious research ecosystem of Italy Milan, the primary objective is to bridge the gap between theoretical device design and clinical application. Milan serves as a critical hub for medical innovation in Europe, hosting world-class institutions such as the Politecnico di Milano and the San Raffaele Scientific Institute. Consequently, this protocol adheres to the highest standards of engineering precision and clinical safety expected in this region.

The device under investigation utilizes photoplethysmography (PPG) and impedance cardiography (ICG) to estimate cardiac output continuously. The role of the Biomedical Engineer in this study is pivotal, ensuring that the signal processing algorithms are robust, the hardware is calibrated according to international standards, and the data acquisition systems are free from electromagnetic interference common in hospital environments.

The primary objective of this experiment is to validate the accuracy and reliability of the prototype device against the gold standard pulmonary artery catheterization method. Secondary objectives include assessing the device's usability by medical staff in the intensive care units (ICUs) of Milanese hospitals and evaluating the long-term stability of the sensors during continuous monitoring.

Specific engineering goals include:

• Verifying signal-to-noise ratios under various patient movement conditions.
• Ensuring compliance with IEC 60601-1 standards for medical electrical equipment safety.
• Optimizing the latency of data transmission to the central monitoring station.

Given the location in Italy Milan, this experiment strictly adheres to the Italian Legislative Decree 211/2003, which implements the EU Clinical Trials Directive. Furthermore, the protocol complies with the General Data Protection Regulation (GDPR) regarding the handling of sensitive patient health data. All procedures have been reviewed and approved by the local Ethics Committee of the ASST (Azienda Socio-Sanitaria Territoriale) of Milan.

The Biomedical Engineer is responsible for ensuring that all devices used are CE-marked or are being tested under an Investigational Medical Device (IMD) exemption. Informed consent must be obtained from all participants or their legal representatives prior to the initiation of any data collection.

4.1 Study Design

This is a prospective, single-center, observational study conducted in the ICU of a major hospital in Milan. The study will enroll 50 adult patients requiring hemodynamic monitoring. The Biomedical Engineer will oversee the setup of the monitoring equipment, ensuring proper calibration before each patient enrollment.

4.2 Equipment and Materials

The experimental setup includes the prototype monitoring device, reference-grade ECG machines, and standard ICU monitoring systems. All equipment will be inspected for safety by the Biomedical Engineer prior to use. The data acquisition system will be synchronized using a GPS-disciplined clock to ensure temporal accuracy across all data streams.

4.3 Procedure

1. Calibration: The Biomedical Engineer will perform a zero-calibration of the pressure transducers and verify the integrity of the PPG sensors.
2. Application: Sensors will be applied to the patient's finger and thorax according to the manufacturer's instructions.
3. Data Collection: Continuous data will be recorded for a period of 24 hours. Simultaneous measurements will be taken using the reference method at hourly intervals.
4. Interference Check: The engineer will monitor for electromagnetic interference from other hospital equipment, such as defibrillators and infusion pumps, which are prevalent in Milan's high-tech ICUs.

Data analysis will be performed using custom software developed by the Biomedical Engineering team. The primary metric for accuracy will be the mean absolute percentage error (MAPE) between the prototype device and the reference method. Statistical analysis will be conducted using R software, with a significance level set at p < 0.05.

The Biomedical Engineer will also analyze the raw signal data to identify artifacts and improve the filtering algorithms. This iterative process is essential for refining the device before it can be considered for broader clinical use in Italy and beyond.

Potential risks include skin irritation from sensor adhesives and minor discomfort from the reference catheterization. The Biomedical Engineer will ensure that all electrical connections are secure and that the device does not exceed safe limits for current leakage. In the event of a device malfunction, the protocol mandates immediate disconnection and notification of the clinical team.

This Experiment Protocol provides a comprehensive framework for the validation of a novel biomedical device in the context of Italy Milan. By leveraging the expertise of a Biomedical Engineer and adhering to strict regulatory and ethical standards, this study aims to contribute significantly to the field of hemodynamic monitoring. The successful completion of this protocol will pave the way for the commercialization of the device, ultimately improving patient care in intensive care settings across Europe.